ADIA's passive 2.1% stake is a routine institutional holding for a sovereign wealth fund. No change in control intent or activist pressure. Monitor for any future 13D conversion or stake increases above 5%.
Price Chart
Executive Summary
Abu Dhabi Investment Authority (ADIA) filed an amended Schedule 13G disclosing a passive 2.1% stake in Eikon Therapeutics as of September 30, 2026, holding 1,147,138 shares through its wholly owned subsidiary Platinum Falcon B 2018 RSC Limited. This is a new filing by ADIA, not an amendment to a prior ADIA filing, and represents a modest passive position in a clinical-stage biotech. The filing is routine and does not signal activist intent.
Key Financial Metrics
Key Facts
- ADIA holds 1,147,138 shares of Eikon Therapeutics common stock, representing 2.1% of shares outstanding.
- Shares are held directly by ADIA's wholly owned subsidiary, Platinum Falcon B 2018 RSC Limited.
- The stake is based on 54,165,030 shares outstanding as of August 3, 2026, per Eikon's Form 10-Q.
- ADIA certifies the shares were not acquired with the purpose of changing or influencing control of the issuer.
- This is a new filing by ADIA; no prior ADIA 13G for Eikon appears in the provided cross-filing context.
Financial Impact
Passive 2.1% stake valued at approximately $1.15M based on share count; no material financial impact.
Risk Factors
- ADIA could increase or decrease the stake without further disclosure until crossing the 5% threshold.
- No indication of activist intent; passive filing limits read-through for near-term catalysts.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001104659-26-113112 |
| Document: 0001104659-26-113112-index.html | 0001104659-26-113112 |
| Document: 0001104659-26-113112.txt | 0001104659-26-113112 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $7.26 (−2.94%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $7.26 (−2.94%) |
Oct 23, 2026 2d ago | 8-K | $8.01 | awaiting T+20 | — | $7.26 (−9.36%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $7.26 (−3.71%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $7.26 (−0.95%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $7.26 (−19.15%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $7.26 (−32.34%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $7.26 (−33.76%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $7.26 (−34.30%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $7.26 (−24.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers